Report Overview

The China cardiovascular therapeutics market size stood at around USD 8.1 billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

The prevalence of CVD in China has been increasing continuously since 2006. Of the approximately 290 million patients with CVD the major portion of patients are suffering from strokes, Coronary and pulmonary heart diseases.

The comparison on the prevalence of CVD in china can be attributed to the fact that the mortality rate due to CVD is more than any other disease in china. Nearly 45% of the patients in china are suffering from cardiovascular diseases.

The statistics of WHO says that the mortality rate of people suffering from corona and CVD at the same time is very high. Rising government initiative and more allocation of funds by manufacturers to cater drugs to the large number of patients.



Market Drivers

Rising cases of CVD are the id the major driving factor for the growth of therapeutics market in china. The accelerated socio-economic progress owing to lifestyle changes, urbanization, and accelerated population. The prevalence of unhealthy lifestyle among people like changing food habits, drinking & smoking has increased the risk of cardiovascular diseases and the intake of CVD drugs among the patients.

The major restraint challenge for this market is the accessibility and price of these drugs. Also, the augmenting healthcare infrastructure is also a problem with these therapeutics areas.